ArticleNeurosurgical review2026
Microsurgical reinforced radiculoplasty for symptomatic sacral Tarlov cysts in children: a retrospective study assessing safety and efficacy.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptomatic sacral Tarlov cysts are rare in the pediatric population. Traditional surgical methods are associated with high recurrence rates and risks of neurological injury. Microsurgical reinforced radiculoplasty (MRR), which focuses on reconstructing the nerve root sleeve to obliterate the cerebrospinal fluid communication, may offer a superior alternative. This study aimed to evaluate the safety and efficacy of MRR in children. We conducted a retrospective analysis of 24 consecutive pediatric patients (<18 years) with symptomatic sacral Tarlov cysts who underwent MRR at our institution between March 2021 and August 2025. The primary outcome was the change in the Japanese Orthopaedic Association (JOA) score for low back pain. Secondary outcomes included symptomatic improvement rates, cyst reduction on MRI, and perioperative complications. The mean age was 15.14 ± 2.63 years. The mean preoperative JOA score significantly improved from 19.58 ± 1.47 to 24.04 ± 2.01 at the final follow-up (mean 18.68 ± 11.33 months) (P < 0.001). All JOA subscales except bladder function showed significant improvement (P < 0.05), with no statistical significance in bladder function (P=0.16). Symptom improvement rates were 89.47% for lumbosacral pain, 87.5% for sensory disturbances, 83.33% for limb weakness, and 100% for both bowel and urinary dysfunction. Postoperative MRI demonstrated significant cyst reduction or resolution in all patients, with no recurrence observed during the follow-up period. Two minor complications (wound fat liquefaction and CNS infection) occurred and resolved with conservative management; no serious surgery-related neurological deficits were observed. In this preliminary study, MRR appears to be a safe and effective treatment for symptomatic sacral Tarlov cysts in children, resulting in significant neurological functional improvement and excellent cyst control with a favorable safety profile. It represents a promising nerve-sparing surgical strategy for this challenging pediatric condition based on preliminary clinical evidence. Further large sample, multicenter prospective studies with long-term follow-up are urgently needed to validate these short-term findings.
Indexed as
Identifiers
41917373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.